|
21 Nov 2023 |
Sandoz launches Hyrimoz® (adalimumab) high-concentration formulation in Europe, aiming to improve patient care
|
|
21 Nov 2023 |
Myricx Bio Enters into an Exclusive Antibody License Agreement with WuXi Biologics
|
|
21 Nov 2023 |
Janssen Submits Supplemental Biologics License Application to U.S. FDA Seeking Approval of RYBREVANT® (amivantamab-vmjw) Plus Chemotherapy for the Treatment of Patients with EGFR-Mutated Non-Small Cell Lung Cancer Who Progressed on or after Osimertinib
|
|
20 Nov 2023 |
Antibody Target, Technology & Pipeline Database: a cost-effective tool to stay tuned with latest information about therapeutic antibodies
|
|
17 Nov 2023 |
Almirall Receives European Commission Approval of EBGLYSS® (lebrikizumab) for Moderate-to-Severe Atopic Dermatitis
|
|
17 Nov 2023 |
Vigil Neuroscience Reports Positive Interim Data from Phase 2 IGNITE Proof-of-Concept Clinical Trial Evaluating Iluzanebart (VGL101) as a Treatment for ALSP and from Ongoing Natural History Study ILLUMINATE
|
|
17 Nov 2023 |
Antengene Presents Encouraging Clinical Data from Four Pipeline Programs at the 2023 R&D Day
|
|
17 Nov 2023 |
FDA Approves Merck’s KEYTRUDA® (pembrolizumab) Plus Chemotherapy as First-Line Treatment for Locally Advanced Unresectable or Metastatic HER2-Negative Gastric or Gastroesophageal Junction (GEJ) Adenocarcinoma
|
|
16 Nov 2023 |
Q32 Bio Regains Worldwide Rights to Bempikibart (ADX-914) from Amgen
|
|
16 Nov 2023 |
argenx Announces European Commission Approval of Subcutaneous VYVGART® (efgartigimod alfa) for Generalized Myasthenia Gravis
|
|
16 Nov 2023 |
Alentis Therapeutics Doses First Patient in Phase 1/2 Clinical Trial of ALE.C04 in Head and Neck Squamous Cell Carcinoma (HNSCC)
|
|
15 Nov 2023 |
SciRhom Files Clinical Trial Application for First-in-Human Trials of Novel Antibody Against Autoimmune Diseases
|
|
15 Nov 2023 |
Alvotech and JAMP Pharma Announce Receipt of Marketing Authorization for Jamteki (AVT04), the First Biosimilar of Stelara® (ustekinumab)
|
|
15 Nov 2023 |
Update on PACIFIC-2 Phase III trial of Imfinzi concurrently administered with platinum-based chemoradiotherapy in unresectable, Stage III non-small cell lung cancer
|
|
15 Nov 2023 |
Chemomab Presents New Clinical Data Supporting CM-101's Anti-Fibrotic/Anti-Inflammatory Activity in Patients with Liver Fibrosis and New Data Highlighting Unique Association of Its CCL24 Target with Key PSC Pathways at AASLD's The Liver Meeting® 2023
|
|
15 Nov 2023 |
Mozart Therapeutics Presents Preclinical Data for MTX-101, a Novel Bispecific CD8 Treg Modulator for Treatment of Autoimmune Diseases, at American College of Rheumatology Convergence 2023
|
|
15 Nov 2023 |
Alpine Immune Sciences Presents New Translational Data on Acazicolcept in Systemic Lupus Erythematosus at American College of Rheumatology Convergence 2023
|
|
15 Nov 2023 |
EyeBio Announces Expansion of Series A to $130 Million, Advances Development of Restoret for Retinal Diseases
|
|
15 Nov 2023 |
MBrace Therapeutics Raises $85 Million Series B Financing to Advance Oncology Pipeline of Innovative Antibody Drug Conjugate Candidates
|
|
15 Nov 2023 |
TRexBio Announces Development Candidate, TRB-061, a Novel TNFR2 Agonist for the Treatment of Inflammatory Diseases
|
|
13 Nov 2023 |
First Patient Dosed in Phase III ProstACT GLOBAL Study of Antibody-based Prostate Cancer Therapy Candidate, TLX591
|
|
13 Nov 2023 |
Anthos Therapeutics' Novel Dual-Acting Factor XI/XIa Inhibitor, Abelacimab 150 mg, Demonstrated a 67% Reduction in the Primary Endpoint of Major or Clinically Relevant Non-Major Bleeding Compared with Rivaroxaban in Patients with Atrial Fibrillation
|
|
10 Nov 2023 |
Astria Therapeutics Presents New Phase 1a Data Confirming Potential for STAR-0125 to Prevent Hereditary Angioedema Attacks with Dosing 2 or 4 Times Per Year at the 2023 American College of Allergy, Asthma, and Immunology Annual Scientific Meeting
|
|
09 Nov 2023 |
Trishula Therapeutics Initiates Phase 2 Trial of TTX-030, an Anti-CD39 Antibody, in First Line Metastatic Pancreatic Cancer Patients
|
|
09 Nov 2023 |
Imfinzi plus bevacizumab met primary endpoint for progression-free survival in liver cancer eligible for embolisation in EMERALD-1 Phase III trial
|
